Harry Welten

Biography

 Harry Welten is Chief Financial Officer (“CFO”) of Kuros. From June 2010 to January 2016 he served as executive vice president and CFO of Cytos. He has more than 20 years of international senior executive experience, sixteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the CFO at Nitec Pharma, which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the CFO at Arpida, which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a director at UBS Warburg in New York/NY, USA, following various senior positions within the UBS Group. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Anokion, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York/NY, USA. Mr. Welten is Swiss citizen.

Research Interest

 Banking and Finance